Condition: Acute Lymphoblastic Leukemia, Pediatric · Sponsor: Martin Schrappe
The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group. The leukemia cells present themselves with quite differently activated regulatory mechanisms of the malignant phenotype. The introduction of more accurate methods of assessing therapy response ("minimal residual disease \[MRD\] tests") has provided new insights into very different mechanisms of action, including factors influenced by host factors; this has had practical clinical consequences for the use of more individualized therapy. Multimodal therapies have enabled a cure level of over 80% for ALL in this age group. However, the own and international study data show that the therapy toxicity of the contemporary chemotherapy concepts has become unacceptably high, in particular with respect to those intensified therapies used for the treatment of patients at high risk of ALL relapse. The AIEOP-BFM ALL 2017 study therefore aims for an innovative integrated approach that will not only adapt the risk stratification to new prognostic markers using more comprehensive diagnostics, but above all, qualitatively reorient the therapy. The most important consequence will be that this study is testing immunotherapy with the bispecific antibody blinatumomab as an alternative to particularly intensive and toxic chemotherapy elements in precursor B-cell ALL (pB-ALL) patien…
This description comes directly from the study's public registry record.
Anja Möricke, MD · +4943150020150 · a.moericke@pediatrics.uni-kiel.de
Lile Bauer · +4943150020152 · lile.bauer@uksh.de
Always discuss trial participation with your own doctor first.
| Sydney Children's Hospital | Sydney, Australia | Recruiting |
| The Children's Hospital at Westmead | Westmead, Australia | Recruiting |
| Univ.Klinik für Kinder- und Jugendheilkunde Graz | Graz, Austria | Recruiting |
| Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck | Innsbruck, Austria | Recruiting |
| Kepler Universitätsklinikum | Linz, Austria | Recruiting |
| LKH Salzburg | Salzburg, Austria | Recruiting |
| St. Anna Kinderspital | Vienna, Austria | Recruiting |
| University Hospital Brno | Brno, Czechia | Recruiting |
| Regional Hospital České Budějovice | České Budějovice, Czechia | Recruiting |
| University Hospital Hradec Králové | Hradec Králové, Czechia | Recruiting |
| University Hospital Olomouc | Olomouc, Czechia | Recruiting |
| University Hospital Ostrava-Poruba | Ostrava-Poruba, Czechia | Recruiting |
+ 103 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03643276